A Phase 2 Open-Label, Single Arm Study of Tucatinib in Combination with Trastuzumab and Capecitabine in Participants with Previously Treated Locally Advanced Unresectable or Metastatic HER2+ Breast Carcinoma

TUKYSA Tucatinib PHASE II Thu, 04/08/2021 - 12:00 NCT04721977 C4251013 Public Disclosure Synopsis .pdf(137.62 KB) N https://clinicaltrials.gov/study/NCT04721977 C4251013 (MK-7119-001)